2026 NPPES data Pharmacotherapy Pharmacist NPI 1902920721 PHARMD
Verify on CMS →

LOK SHUN (LENNY) CHAN, PHARMD

Pharmacotherapy Pharmacist in SAN FRANCISCO, California. CMS National Plan and Provider Enumeration System profile including specialty classification, practice address, and Medicare prescribing data when reported.

Federal data — no proprietary rating. PlainDoctor publishes the actual CMS NPPES and Medicare records — NPI registration, specialty, practice location, and prescribing data — without a composite score or editorial opinion on top. Every field traces to a federal source.
Prescribing volume
1K
Medicare Part D claims · 180 beneficiaries · Pharmacotherapy Pharmacist avg: 397
Generic prescribing
65%
generic claims · 35% brand-name · higher generic rates reduce patient out-of-pocket costs

What the federal data shows

LOK SHUN (LENNY) CHAN, PHARMD filed 1,473 Medicare Part D claims in 2023 as a Pharmacotherapy Pharmacist in SAN FRANCISCO, California, prescribing 65% generic.

1K
Part D claims, 2023
65%
generic prescribing

Every figure on this page comes straight from federal CMS records (NPPES, Medicare Part D, MIPS, Open Payments) — no proprietary rating or editorial opinion is applied.

LOK SHUN (LENNY) CHAN, PHARMD's Medicare Part D volume vs every U.S. prescriber

Total Medicare Part D claims, 2023 — across all CMS prescribers nationally

1,473 Top 20% higher than 80% of 1,370,886 prescribers

0–200: 670,926 prescribers (49%). Below this entry. 200–400: 182,923 prescribers (13%). Below this entry. 400–600: 90,619 prescribers (7%). Below this entry. 600–800: 56,224 prescribers (4%). Below this entry. 800–1,000: 40,919 prescribers (3%). Below this entry. 1,000–1,200: 31,827 prescribers (2%). Below this entry. 1,200–1,400: 26,224 prescribers (2%). Below this entry. 1,400–1,600: 21,710 prescribers (2%). This entry sits in this band. 1,600–1,800: 19,072 prescribers (1%). Above this entry. 1,800–2,000: 16,451 prescribers (1%). Above this entry. 2,000–2,200: 213,991 prescribers (16%). Above this entry. This provider 0 2K+ every Part D prescriber (claims/yr), bucketed by value

Each bar is a band; taller bars hold more prescribers. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count, share, and where it sits relative to this entry.

Source CMS Medicare Part D Prescriber Public Use File · 2023

What does the federal data show about LOK SHUN (LENNY) CHAN, PHARMD?

Quality data not reported

NPI registry status

Active

Issued 03/19/2007

NPI 1902920721

Primary specialty

Pharmacotherapy Pharmacist

Mid-sized

5,925 US NPIs in this specialty

Medicare Part D claims

1,473 271% vs specialty avg

2023 prescription claims

Specialty avg: 397

Specialty distribution in California

How Pharmacotherapy Pharmacist compares to other specialties among California providers

California providers

Pharmacotherapy Pharmacist share within California

1. Pharmacotherapy Pharmacist42%2. Internal medicine21%3. Family medicine17%4. Surgical12%5. Pediatric8%
Pharmacotherapy Pharmacist share within California

Specialty board-certification context

Estimated specialty board-certified rate — Pharmacotherapy Pharmacist (ABMS / AOA reference)

Quality data not reported
Est. board-certified rate
78%
Pharmacotherapy Pharmacist ABMS/AOA estimate

Est. board-certified rate (Pharmacotherapy Pharmacist) — ABMS / AOA estimate

0%100%78%
Est. board-certified rate (Pharmacotherapy Pharmacist) — ABMS / AOA estimate

The Merit-based Incentive Payment System (MIPS) scores providers 0–100 across four performance categories: Quality, Cost, Promoting Interoperability, and Improvement Activities, weighted under 42 CFR §414.1380. Reporting is voluntary for many small practices, so absence of a MIPS score is not a quality signal.

Board certification through an ABMS or AOA member board signals voluntary post-licensure examination plus continuous Maintenance of Certification cycles. Verify any individual provider's status through certificationmatters.org (ABMS) or osteopathic.org (AOA).

LOK SHUN (LENNY) CHAN, PHARMD appears in the CMS NPPES registry as a Pharmacotherapy Pharmacist provider holding PHARMD credentials at 2789 25TH ST STE 202, SAN FRANCISCO, CA, 94110, with a listed phone of (415) 206-2330. NPI 1902920721 was issued on 03/19/2007. Because NPPES data is self-reported by the provider and refreshed monthly, the address, phone, and specialty reflect what CHAN most recently submitted to CMS rather than a vetted directory listing, which is why patients should always confirm the practice is still at this location before scheduling.

Medicare Part D records for calendar year 2023 show 1,473 prescription claims written by this provider, covering 180 Medicare beneficiaries and totaling roughly $670K in drug spend, split 35% brand-name and 65% generic by claim count. These figures capture only Medicare Part D — commercial insurance, Medicaid, and cash-pay prescriptions are not included, and any drug-beneficiary cell under 11 is suppressed by CMS for patient privacy.

Pharmacotherapy Pharmacist is a mid-sized specialty nationwide, with 5,925 enrolled providers across 53 states and an average of 397 Part D claims per prescriber, so the context for interpreting these metrics differs meaningfully from a primary-care baseline. Important: PlainDoctor is a directory of publicly available government data, not medical advice, a malpractice database, or a quality rating. Inclusion here does not imply a recommendation, and absence of complaints or sanctions on this page does not mean none exist — always verify credentials through the NPPES NPI Registry, your state medical board, and the ABMS or AOA before making healthcare decisions.

Practice Address

2789 25TH ST STE 202
SAN FRANCISCO, CA 94110

Provider Details

NPI 1902920721
Specialty Pharmacotherapy Pharmacist
Credentials PHARMD
Gender Male
NPI Issued 03/19/2007

License & disciplinary context — California MBC 2023 annual report

Aggregate state board data only — NOT a determination of any individual provider's status. The figures below describe statewide disciplinary activity across all ~150K California medical licensees in 2023 — they are NOT specific to LOK SHUN (LENNY) CHAN, PHARMD. To verify LOK SHUN (LENNY) CHAN, PHARMD's current license status, search the MBC public license lookup directly, or check the Federation of State Medical Boards (FSMB) verification service.

576
Total board actions, California 2023
Across 556 cases
3.84
Actions per 1,000 licensees
California statewide rate
probation
Most common action type
186 cases

MBC publishes annual disciplinary statistics as part of public-record reporting under each state's Administrative Procedure Act. See the full breakdown by action type and year on the California disciplinary trends page. Cross-checked against FSMB U.S. Medical Regulatory Trends.

Brand vs generic prescribing mix · Above average

LOK SHUN (LENNY) CHAN, PHARMD — brand share 35.0%
Specialty average (est.)

35% brand-name claims vs 65% generic, on 1,473 2023 Medicare Part D claims.

The federal Medicare Part D Generic Dispensing Rate national benchmark sits near 90% generic / 10% brand for primary-care prescribers, per CMS Office of the Actuary 2024 estimates. Higher brand share is common in specialty prescribing where generic equivalents are not available.

Medicare Part D Prescribing Data

CMS Medicare Part D prescriber-level data for calendar year 2023.

1,473
Total Claims
$670K
Total Drug Cost
180
Medicare Beneficiaries

Prescribing Breakdown

30-Day Fills
3,832
Total Day Supply
114,058
Brand vs Generic
35% brand / 65% generic
Brand Drug Cost
$630K
Generic Drug Cost
$33K

Patient Demographics

Average Patient Age
74.0 years
Avg HCC Risk Score
1.16
Gender Split
55% female / 45% male

Top Prescribed Drugs (Medicare Part D)

Top drugs by claim count for calendar year 2023. Based on Medicare Part D data only.

What LOK SHUN (LENNY) CHAN, PHARMD prescribes most

Top Medicare Part D drugs by claim count, 2023

claims
Source CMS Medicare Part D Prescriber Public Use File As of 2023
Drug Claims
Amlodipine Besylate
164
Losartan Potassium
112
Atorvastatin Calcium
101
Jardiance
Empagliflozin
96
Metformin Hcl Er
Metformin Hcl
77
Glipizide
70
Novolog Flexpen
Insulin Aspart
53
Ozempic
Semaglutide
50
Hydrochlorothiazide
45
Rybelsus
Semaglutide
45

* Counts below 11 are suppressed by CMS for patient privacy. Generic names shown where available from CMS Part D data.

Pharmacotherapy Pharmacist Overview

How LOK SHUN (LENNY) CHAN, PHARMD fits within the Pharmacotherapy Pharmacist landscape nationally.

5,925
Pharmacotherapy Pharmacist Providers in US
53
States with Pharmacotherapy Pharmacist
397
Avg Claims per Provider

LOK SHUN (LENNY) CHAN, PHARMD's 1,473 claims are above the specialty average of 397.

Nearby Pharmacotherapy Pharmacist Providers in California

Other clinicians with the same primary specialty enrolled in California, drawn from the same CMS NPPES roster as CHAN.

Compare Pharmacotherapy Pharmacist nationally: see state-by-state distribution →

Frequently Asked Questions

What is LOK SHUN (LENNY) CHAN, PHARMD's specialty?
LOK SHUN (LENNY) CHAN, PHARMD specializes in Pharmacotherapy Pharmacist and practices in SAN FRANCISCO, California. Credentials: PHARMD.
How much does LOK SHUN (LENNY) CHAN, PHARMD prescribe under Medicare Part D?
In 2023, LOK SHUN (LENNY) CHAN, PHARMD wrote 1,473 Medicare Part D claims totaling $670K in drug costs for 180 beneficiaries.
Where is LOK SHUN (LENNY) CHAN, PHARMD located?
LOK SHUN (LENNY) CHAN, PHARMD is located at 2789 25TH ST STE 202, SAN FRANCISCO, CA, 94110. Phone: (415) 206-2330.
What is LOK SHUN (LENNY) CHAN, PHARMD's NPI number?
LOK SHUN (LENNY) CHAN, PHARMD's National Provider Identifier (NPI) is 1902920721, issued on 03/19/2007.
Does LOK SHUN (LENNY) CHAN, PHARMD prescribe more brand-name or generic drugs?
LOK SHUN (LENNY) CHAN, PHARMD's prescribing is 35% brand-name and 65% generic drugs by claim count, with $630K in brand drug costs.
How many Pharmacotherapy Pharmacist providers are there in the US?
There are 5,925 Pharmacotherapy Pharmacist providers across 53 states in the US. The average Pharmacotherapy Pharmacist provider writes 397 Medicare Part D claims per year.
What drugs does LOK SHUN (LENNY) CHAN, PHARMD prescribe most often?
Based on 2023 Medicare Part D data, LOK SHUN (LENNY) CHAN, PHARMD's most frequently prescribed drugs include Amlodipine Besylate, Losartan Potassium, Atorvastatin Calcium. This reflects Medicare Part D prescriptions only and does not include commercial insurance or other payer types.
Does LOK SHUN (LENNY) CHAN, PHARMD accept Medicare?
LOK SHUN (LENNY) CHAN, PHARMD appears in CMS Medicare data with 1,473 Part D claims and 180 Medicare beneficiaries in 2023. Contact the provider's office directly to confirm current Medicare enrollment and accepted plans.
How can I verify LOK SHUN (LENNY) CHAN, PHARMD's credentials?
LOK SHUN (LENNY) CHAN, PHARMD's NPI is 1902920721 with credentials PHARMD. You can verify this through the NPPES NPI Registry, check state medical board records, and confirm board certification through the ABMS or AOA.

Data Sources

Provider Directory
CMS National Plan and Provider Enumeration System (NPPES), download.cms.gov/nppes, updated monthly. Contains NPI, specialty, credentials, and practice location.
Specialty Classification
NUCC Health Care Provider Taxonomy (nucc.org), the industry standard for classifying provider specialties in Medicare and Medicaid billing.
Prescribing Data
CMS Medicare Part D Prescriber Public Use File (2023). Includes claims, drug costs, beneficiaries, and opioid prescribing rates.
Limitations
Provider data is self-reported to CMS. Prescribing data reflects Medicare Part D only and does not include commercial insurance, Medicaid, or cash prescriptions. Claims below 11 beneficiaries are suppressed by CMS for privacy.

See our complete data methodology for details on how we collect and process government data.

Data as of April 2026 (NPPES) / 2023 (Medicare Part D). Source: Centers for Medicare & Medicaid Services (CMS).

Disclaimer: Data from CMS NPPES and Medicare Part D. PlainDoctor does not rate or rank providers. Provider information is self-reported and may not be current. Always verify information directly with the provider. About · Methodology